COVID-19 vaccine: Covaxin effective against Indian, UK COVID-19 strains, says Bharat Biotech
3 years, 7 months ago

COVID-19 vaccine: Covaxin effective against Indian, UK COVID-19 strains, says Bharat Biotech

Firstpost  

The study was conducted in collaboration with the National Institute of Virology and Indian Council of Medical Research, Bharat Biotech said Bharat Biotech on Sunday said its COVID-19 vaccine ‘‘Covaxin’’ has been found to be effective against coronavirus strains found in India and the UK. Citing a study published in peer-reviewed medical journal Clinical Infectious Diseases, the Hyderabad-based vaccine major noted that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B.1.617 and B.1.1.7, first identified in India and the UK, respectively. Yet another feather in its cap,” Bharat Biotech co-founder and joint managing director Suchitra Ella said in a tweet. The study found a modest reduction in neutralisation by a factor of 1.95 against B.1.617 variant compared to vaccine variant D614G, Bharat Biotech noted.

India Indian Bharat Bharat Biotech  b1617  covaxin  biotech  bharat  medical  indian  strains  uk  virology  effective  covid19  study  vaccine  research  india  variants

History of this topic

Recent breakthrough in COVID-19 vaccination: Indian Immunologicals Ltd unveils first needle-free booster vaccine
3 months, 3 weeks ago

Recent breakthrough in COVID-19 vaccination: Indian Immunologicals Ltd unveils first needle-free booster vaccine

Hindustan Times  

In a recent development, Hyderabad-based Indian Immunologicals Ltd in collaboration with Griffith University in Australia has made a significant breakthrough in COVID-19 vaccination technology. Indian Immunologicals Ltd unveils first needle-free booster vaccine “This accomplishment signifies a major step forward in our battle against COVID-19. According to the press release, the innovative vaccine sports an attenuated formulation that uses advanced codon …

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda
4 months, 3 weeks ago

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda

The Hindu  

The Indian Council of Medical Research has received ₹172 crore as royalty from Bharat Biotech International Limited for jointly developing Covaxin, an indigenously developed vaccine for COVID-19, Union Health Minister J.P. Nadda said, during Question Hour in the Lok Sabha on Friday. Covaxin was jointly developed by ICMR, National Institute of Virology, and Bharat Biotech International Ltd, in two phases. …

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR
6 months ago

Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR

The Hindu  

India’s first indigenously developed coronavirus vaccine, Covaxin, was a joint collaboration between the Indian Council of Medical Research and the Hyderabad-based Bharat Biotech International Limited with intellectual property rights jointly shared between the two organisations. The Minister’s statement said the ICMR would provide a “well characterised” virus strain for vaccine development, the BBIL would develop the final vaccine formulation and, …

Why COVID vaccine safety needs scrutiny | Explained
6 months, 4 weeks ago

Why COVID vaccine safety needs scrutiny | Explained

The Hindu  

The story so far: The Indian Council for Medical Research issued a letter to the researchers of Banaras Hindu University last week, countering their study on the side effects of India’s indigenous vaccine for COVID — Covaxin. The one-year observational, follow-up study titled ‘Long-term safety analysis of the BBV152 coronavirus vaccine in adolescents and adults: Findings from a one-year prospective …

1 in 3 Covaxin takers reported adverse events, BHU study claims
7 months, 1 week ago

1 in 3 Covaxin takers reported adverse events, BHU study claims

Hindustan Times  

A one-year follow-up study conducted by researchers at Banaras Hindu University has found that nearly one-third of individuals who received Bharat Biotech's Covaxin reported 'adverse events of special interest'. Read: AstraZeneca Covid vaccine related to another rare but deadly blood clotting disorder Adverse Events of Special Interest: Around 33% of participants reported AESI, with new-onset skin and subcutaneous disorders, general …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 1 week ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official
7 months, 2 weeks ago

AstraZeneca's Covishield Showed Lowest Incidence of Side Effects in India Versus Globally, Says Top Govt Official

News 18  

AstraZeneca’s vaccine has demonstrated the lowest incidence of side effects in India compared to the global average, a top government official involved in the national roll-out of Covid-19 vaccination told News18. “But only around 50 cases witnessed Thrombosis with Thrombocytopenia Syndrome — a rare side effect caused by the jab — of the 180 crore doses administered against 4 to …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

AstraZeneca pulls its COVID-19 vaccine from the European market
7 months, 2 weeks ago

AstraZeneca pulls its COVID-19 vaccine from the European market

Associated Press  

LONDON — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator. In an update on the European Medicines Agency’s website Wednesday, the regulator said that the approval for AstraZeneca’s Vaxzevria had been withdrawn “at the request of the marketing authorization holder.” AstraZeneca’s COVID-19 vaccine was first given …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
7 months, 3 weeks ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

Covishield more effective than Covaxin: Study
9 months, 2 weeks ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
9 months, 2 weeks ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

Global study quantifies rise in blood clots, heart inflammation following COVID-19 vaccination
10 months ago

Global study quantifies rise in blood clots, heart inflammation following COVID-19 vaccination

The Hindu  

One of the largest assessments of its kind, spanning 99 million people and investigating reports of adverse reactions following COVID-19 vaccination, found that instances of Guillain Barre Syndrome, myocarditis, pericarditis and cerebral venous sinus thrombosis were at least 1.5 times more than expected following inoculation with mRNA and ChadOX1 vaccines. The Global Covid Vaccine Safety Project, which made the assessment, …

With State prod, India can be world leader in vaccines
10 months, 4 weeks ago

With State prod, India can be world leader in vaccines

Hindustan Times  

The World Health Organization activated its incident management support team as part of its emergency response framework on the emergence of a cluster of atypical pneumonia cases emerging from Wuhan, China, on January 1, 2020. India, the dark horse in the vaccine race, did the unexpected and against all odds, approving EUA to two vaccines — “made in India” Covishield …

New COVID variant JN.1: Health Ministry says no need for booster dose
1 year ago

New COVID variant JN.1: Health Ministry says no need for booster dose

The Hindu  

Following the Union Health Ministry direction that States be alert and prepared for any possible surge in COVID-19 cases following the emergence of the new variant JN.1, senior health officials said that there is no move to recommend administration of vaccine booster dose for India. India saw a single-day rise of 656 COVID-1 infections while the active cases have increased …

Covid in India Highlights: Maharashtra reports nine JN.1 infections
1 year ago

Covid in India Highlights: Maharashtra reports nine JN.1 infections

Hindustan Times  

Covid in India Highlights: India logged a total of 656 fresh cases of Covid-19 infections on December 24. Former AIIMS, Delhi, director Randeep Guleria said the sub-variant JN.1 is “gradually becoming dominant” but observed that it is not causing severe infections or hospitalisations. The World Health Organisation also classified JN.1 into the Variant of Interest category, however, said there is …

COVID-19 Update: India records 260 new cases, total active at 1,828
1 year ago

COVID-19 Update: India records 260 new cases, total active at 1,828

Live Mint  

India reported 260 new cases of COVID-19, with active cases rising to 1,828, as per the latest data from the Union Health Ministry on December 18. Centre Urges States to Heighten Vigilance The central government has written to states and union territories, urging them to maintain "continuous vigilance" in light of the recent surge in COVID-19 cases and the identification …

The Vaccine War: A tale of Indian scientists' triumph over COVID-19 amid the Left's propaganda to undermine indigenous vaccine
1 year, 2 months ago

The Vaccine War: A tale of Indian scientists' triumph over COVID-19 amid the Left's propaganda to undermine indigenous vaccine

Op India  

Recalling the dreadful chapters from the year 2020 when the spread of novel coronavirus in India killed several lives, affected many businesses, and derailed the normal routine lives of almost all is difficult. But Vivek Ranjan Agnihotri, the marvellous director who earlier amazed audiences with movies like ‘The Kashmir Files’ and ‘The Tashkent Files’ has made an attempt to bring …

A new regime: On the Emergency Use Authorisation regime in India and clinical trials
1 year, 5 months ago

A new regime: On the Emergency Use Authorisation regime in India and clinical trials

The Hindu  

Last week, the Drug Controller General of India cleared, under the provisions of ‘emergency use authorisation’, a new mRNA vaccine for COVID-19 developed by Pune-based Gennova Biopharmaceuticals, a pioneer in India in developing mRNA vaccines. More than evidence-based assessment, it was a technicality in India’s ‘New Drugs and Clinical Trials Rules, 2019’ that allowed EUA in India for COVID-19 vaccines. …

India-made mRNA vaccine priced at ₹2,292, will be available as a booster dose
1 year, 6 months ago

India-made mRNA vaccine priced at ₹2,292, will be available as a booster dose

The Hindu  

India’s first indigenously developed mRNA vaccine against the dominant Omicron variant of the COVID-19 coronavirus will cost ₹2,292, Sanjay Singh, CEO, Gennova Biopharmaceuticals, said at a press conference on June 24. The vaccine will for now only be available as a booster or “precaution dose”, that is, somebody who has already been vaccinated thrice will be ineligible as the relevant …

First Omicron-specific mRNA vaccine from India approved by regulators
1 year, 6 months ago

First Omicron-specific mRNA vaccine from India approved by regulators

The Hindu  

India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM, developed by Pune-based Gennova Biopharmaceuticals Ltd, was approved under emergency use guidelines by the Drug Controller General of India late Monday. Gennova CEO Sanjay Singh said that by the time his company got regulatory approvals for GEMCOVAC-19, the demand for primary doses was largely met by other vaccines, however there …

India urges G-20 countries to join vaccine research collaborative in wake of COVID vaccine inequity
1 year, 6 months ago

India urges G-20 countries to join vaccine research collaborative in wake of COVID vaccine inequity

The Hindu  

With the COVID-19 pandemic exposing the acute inequity in vaccine development and access, the Indian government is working in partnership with two leading global non-profits to convene and build consensus among the G-20 member States and others, for a proposed Global Vaccine Research Collaborative. “International cooperation is essential to advance vaccine development for emerging pathogens, and the G-20 can serve …

India’s Winning Formula: Making Healthcare Affordable and Accessible with PPPs
1 year, 6 months ago

India’s Winning Formula: Making Healthcare Affordable and Accessible with PPPs

News 18  

In the last 75 years, India’s progress as a nation has been both inspiring and impressive. Vaccine PPPs during the Covid-19 pandemic It is during the pandemic that India gained a definite advantage in the global health space, when it administered the first dose of the indigenous Covid-19 vaccine Covaxin, in January 2021. Within a year of the emergence of …

At 14,493, India records sharp dip in daily Covid tally, logs 801 new cases
1 year, 7 months ago

At 14,493, India records sharp dip in daily Covid tally, logs 801 new cases

Hindustan Times  

India has logged 801 new coronavirus infections, while the active cases have dipped to 14,493 from 15,515, according to the Union Health Ministry data updated on Monday. According to the ministry's website, 220.66 crore doses of Covid vaccine have been administered in the country so far under the nationwide vaccination drive. The active cases now comprise 0.03 per cent of …

Why It Matters | Does BCG vaccine work for Covid-19 infection?
1 year, 7 months ago

Why It Matters | Does BCG vaccine work for Covid-19 infection?

The Hindu  

What are the facts: The BCG vaccine, typically administered to prevent tuberculosis, did not provide any significant protection against Covid-19 infection to healthcare workers, a new study said. Published in the New England Journal of Medicine, the study’s results stated that 14.7% of the participants who received the bacillus Calmette-Guerin vaccine showed symptoms of Covid-19 infection. In comparison, 12.3% of …

India restarts Covid vaccine production as new infections soar 30% in one day
1 year, 8 months ago

India restarts Covid vaccine production as new infections soar 30% in one day

The Independent  

India is ramping up its vaccine production following a rapid surge in Covid-19 cases driven by a new subvariant dubbed Arcturus. The country recorded 10,158 news Covid cases on Thursday, a 30 per cent surge in one day, according to the federal health ministry data. The company stopped manufacturing Covishield in December 2021 due to dwindling demand and a low …

Serum Institute could resume Covishield production as Covid cases rise
1 year, 8 months ago

Serum Institute could resume Covishield production as Covid cases rise

Live Mint  

The Serum Institute of India could resume production of the Covishield Covid-19 vaccine as infections rise in the country, a company spokesperson said on Wednesday. Dr Amitav Banerjee - an epidemiologist who leads DY Patil Medical College in Pune has earlier said that Covishield carried a ‘double whammy of risk’. Many would perhaps not know that Covishield carries a DNA …

Studies show XBB.1.16 is not clinically more severe
1 year, 8 months ago

Studies show XBB.1.16 is not clinically more severe

Hindustan Times  

The XBB.1.16 sub-variant of the Omicron strain of the SARS-CoV-2 virus that causes Covid does not exhibit higher clinical severity according to preliminary results from laboratory studies being conducted in the country to know disease characteristics, according to people familiar with the matter. According to the World Health Organisation, mutations at position 478 of the SARS-CoV-2 spike protein have been …

Old Covid Vaccines May Have Low Efficacy; India Should Update Covid Boosters, Dr Randeep Guleria Warns
1 year, 8 months ago

Old Covid Vaccines May Have Low Efficacy; India Should Update Covid Boosters, Dr Randeep Guleria Warns

News 18  

Similar to flu shots, India may need to update its Covid-19 boosters with the latest strain of the coronavirus, former director of All India Institute of Medical Sciences, Dr Randeep Guleria told News18.com. A renowned pulmonologist, Dr Guleria said the vaccines in India are currently using the Wuhan strain or the strain which was circulating in December 2019. “But now, …

Active COVID-19 cases in India rise to 21,179
1 year, 8 months ago

Active COVID-19 cases in India rise to 21,179

The Hindu  

India logged 3,038 new coronavirus cases, while the active cases increased to 21,179, according to the Union Health Ministry data updated on Tuesday, April 4, 2023. The COVID-19 case tally was recorded at 4.47 crore The active cases now comprise 0.05 per cent of the total infections and the national COVID-19 recovery rate was recorded at 98.76 per cent, the …

Explained | Should India worry about rising COVID-19 cases?
1 year, 8 months ago

Explained | Should India worry about rising COVID-19 cases?

The Hindu  

The story so far: Prime Minister Narendra Modi this week convened a high-level meeting of the COVID-19 task force. As of March 23, India officially reported 1,300 new coronavirus cases over a 24-hour period bringing the overall tally of active cases to 7,605. Editorial |No cause for alarm: On the Omicron recombinant XBB.1.16 in India He emphasised the need to …

Active COVID-19 cases in country climb to 7,026
1 year, 9 months ago

Active COVID-19 cases in country climb to 7,026

The Hindu  

India recorded 1,134 new coronavirus cases, while the active cases increased to 7,026, according to the Union Health Ministry data updated on March 22. The death toll climbed to 5,30,813 with five deaths with one each reported by Chhattisgarh, Delhi, Gujarat and Maharashtra and one reconciled by Kerala, the data updated at 8 am stated. The active cases now comprise …

‘The Vial’ trailer out: Manoj Bajpayee narrates History TV18's documentary on India’s Covid-19 vaccine journey
1 year, 9 months ago

‘The Vial’ trailer out: Manoj Bajpayee narrates History TV18's documentary on India’s Covid-19 vaccine journey

Firstpost  

India’s Covid-19 vaccination programme has proven to be the world’s largest but how did the nation, led by Prime Minister Narendra Modi, embark on this journey? To find out the details of a historic and unprecedented battle, check out History TV18’s documentary titled ‘The Vial – India’s Vaccine Story’ on March 24, 2023, at 8PM. ‘The Vial’ brings to life …

No Alarming Trend, Says INSACOG Member on Covid Spike But 'Intelligent Pathogen' is Mutating
1 year, 9 months ago

No Alarming Trend, Says INSACOG Member on Covid Spike But 'Intelligent Pathogen' is Mutating

News 18  

There is a noticeable surge in Covid-19 cases but hospitalisation and death rate is not alarming, co-chair at INSACOG’s advisory board, Dr Saumitra Das, told News18.com in an exclusive interaction. So far, the trend of hospitalisation and deaths is not alarming.” He added: “We haven’t seen an alert either from the genome sequencing effort or the sewage surveillance program.” Das, …

COVID-19: Single-day rise of 1,071 fresh cases in India; active tally climb to 5,915
1 year, 9 months ago

COVID-19: Single-day rise of 1,071 fresh cases in India; active tally climb to 5,915

India TV News  

Covid-19 update in India : India saw a single-day rise of over 1,000 fresh COVID-19 cases after 129 days today, while the active cases increased to 5,915, according to the Union health ministry data. A total of 1,071 fresh cases were reported in the county in a span of 24 hours, while the death toll increased to 5,30,802 with three …

Covid vaccine mission is a lesson for the world
1 year, 9 months ago

Covid vaccine mission is a lesson for the world

Hindustan Times  

When Covid-19 began in early 2020, most experts predicted India could face disastrous consequences. India’s response to the pandemic highlighted the underlying strengths of our scientific and technological prowess Not only did India succeed in protecting its population, but it also sent vaccines to other countries, thus proving to the world its capability of developing the first-ever DNA vaccine and …

India saved 3.4mn people through Covid-19 vaccination drive: Report
1 year, 10 months ago

India saved 3.4mn people through Covid-19 vaccination drive: Report

Hindustan Times  

India saved at least 3.4 million lives by undertaking a nationwide Covid-19 vaccination campaign at an unprecedented scale, said a new report released by the Union health minister, Mansukh Mandaviya, on Friday, adding that the vaccination campaign also yielded a positive economic impact by preventing a loss of $18.3 billion. India started its Covid vaccination drive on January 16, 2021, …

‘India’s contribution to Covid vaccines has been tremendous’: CEPI chief
1 year, 10 months ago

‘India’s contribution to Covid vaccines has been tremendous’: CEPI chief

Hindustan Times  

Richard Hatchett, CEO of CEPI who is on a visit to India, spoke to HT about the country gaining attention globally by manufacturing and developing anti-Covid vaccines in less than a year, and lessons learnt from the pandemic. Did the fact that India developed and produced Covid vaccines in less than a year catch global attention? And it wasn’t just …

Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India
1 year, 10 months ago

Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India

Live Mint  

The world's first intranasal heterologous booster dose has begun to be dispatched by Bharat Biotech to hospitals, Executive Chairman Dr. Krishna Ella announced on February 5. He discussed the delivery of vaccines under the bilateral agreement between the Ella Foundation and the UW-Madison Global Health Institute for the establishment of the first-ever UW-Madison One Health Center in India for improving …

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella
1 year, 10 months ago

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella

India TV News  

COVID-19 vaccine : Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday. "We dispatched three lakh doses of the world's first intranasal COVID-19 vaccine to some hospitals two days ago," Ella said. Establishing the UW-Madison Global One Health Centre holds great significance as …

India launches world’s 1st intranasal Covid vaccine: Check price, availability
1 year, 10 months ago

India launches world’s 1st intranasal Covid vaccine: Check price, availability

Hindustan Times  

The world's first made-in-India intranasal Covid-19 vaccine iNCOVACC, manufactured by Bharat Biotech, was launched on Thursday as the country marked its 74th Republic Day. Union health minister Mansukh Mandaviya launched the vaccine and emphasised India's vaccine manufacturing and innovation capability, which he said is appreciated all over the world. "As the world's first intranasal Covid-19 vaccine, this is a glorious …

What is nasal vaccine - iNCOVACC? All you need to know
1 year, 10 months ago

What is nasal vaccine - iNCOVACC? All you need to know

India TV News  

Covid19 nasal vaccine : Union Health Minister Mansukh Mandaviya on Friday launched Bharat Biotech's first India-made nasal Vaccine, iNCOVACC, as a booster shot for Covid19. According to Bharat Biotech, the nasal vaccine is likely to prevent infection, thus, preventing the transmission of the virus. The event saw the Union Minister of State Science & Technology; Minister of State Earth Sciences; …

Centre rolls out first nasal Covid vaccine as booster
1 year, 10 months ago

Centre rolls out first nasal Covid vaccine as booster

Hindustan Times  

India on Thursday rolled out the first nasal vaccine against Covid-19, to be administered as a primary or booster dose for adults, potentially widening the pool of people who may take a third vaccine against the infection, cutting tertiary costs, and easing pressures on supply and storage networks. “Being the world’s first intranasal Covid-19 vaccine, this marks a glorious tribute …

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine
1 year, 10 months ago

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine

Hindustan Times  

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's approval in November for restricted emergency use among adults as a heterologous booster dose. According to a statement issued …

India’s first intra-nasal Covid-19 vaccine iNCOVACC launched
1 year, 10 months ago

India’s first intra-nasal Covid-19 vaccine iNCOVACC launched

Live Mint  

Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched India's first made nasal vaccine against Covid-19 iNCOVACC. "Our nasal vaccine will be officially launched on January 26, on Republic Day," the company's chairman and managing director Krishna Ella said, participating in the 'Face-to-Face with New Frontiers in Science' segment of the IISF, organised at the …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 10 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

COVID-19: Health Minister Mansukh Mandaviya to launch world's 1st 'Made-in-India' nasal vaccine today
1 year, 11 months ago

COVID-19: Health Minister Mansukh Mandaviya to launch world's 1st 'Made-in-India' nasal vaccine today

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya will launch 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday, official sources said. According to the sources, Hyderabad-based Bharat Biotech's Intranasal heterologous booster dose is likely to be available in the market by February first week.Recently, Bharat Biotech announced iNCOVACC® as a booster dose in the country.Earlier this …

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26
1 year, 11 months ago

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26

Hindustan Times  

Bhopal: Bharat Biotech’s nasal Covid-19 vaccine iNCOVACC is expected to be launched on January 26, executive chairman Krishna Ella said at an event on Saturday. “Our nasal vaccine will be officially launched on January 26 on Republic Day,” Ella told students at the Maulana Azad National Institute of Technology in Bhopal, where the India International Science Festival, 2022, is being …

Discover Related